Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Facilitating oligonucleotide delivery: helping antisense deliver on its promise.

× No keyword cloud information.

32 in total

1. Second structural motif for recognition of DNA by oligonucleotide-directed triple-helix formation.

Authors: P A Beal; P B Dervan
Journal: Science Date: 1991-03-15 Impact factor: 47.728

2. A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro.

Authors: A M Gewirtz; B Calabretta
Journal: Science Date: 1988-12-02 Impact factor: 47.728

3. Mutagenesis in mammalian cells induced by triple helix formation and transcription-coupled repair.

Authors: G Wang; M M Seidman; P M Glazer
Journal: Science Date: 1996-02-09 Impact factor: 47.728

4. Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides.

Authors: G Y Wu; C H Wu
Journal: J Biol Chem Date: 1992-06-25 Impact factor: 5.157

5. Inhibition of DNA binding proteins by oligonucleotide-directed triple helix formation.

Authors: L J Maher; B Wold; P B Dervan
Journal: Science Date: 1989-08-18 Impact factor: 47.728

6. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides.

Authors: C F Bennett; M Y Chiang; H Chan; J E Shoemaker; C K Mirabelli
Journal: Mol Pharmacol Date: 1992-06 Impact factor: 4.436

7. Role of the KIT protooncogene in normal and malignant human hematopoiesis.

Authors: M Z Ratajczak; S M Luger; K DeRiel; J Abrahm; B Calabretta; A M Gewirtz
Journal: Proc Natl Acad Sci U S A Date: 1992-03-01 Impact factor: 11.205

Review 8. The anti-gene strategy: control of gene expression by triplex-forming-oligonucleotides.

Authors: C Hélène
Journal: Anticancer Drug Des Date: 1991-12

9. Evidence that a triplex-forming oligodeoxyribonucleotide binds to the c-myc promoter in HeLa cells, thereby reducing c-myc mRNA levels.

Authors: E H Postel; S J Flint; D J Kessler; M E Hogan
Journal: Proc Natl Acad Sci U S A Date: 1991-09-15 Impact factor: 11.205

Review 10. Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonucleotides.

Authors: C Hélène
Journal: Eur J Cancer Date: 1991 Impact factor: 9.162

14 in total

Review 1. Update on metastatic breast cancer.

Authors: E A Perez
Journal: Curr Oncol Rep Date: 1999-09 Impact factor: 5.075

Review 2. Preclinical and clinical pharmacology of antisense oligonucleotides.

Authors: E G Marcusson; B R Yacyshyn; W R Shanahan; N M Dean
Journal: Mol Biotechnol Date: 1999-08 Impact factor: 2.695

3. Peptide nucleic acid-targeted mutagenesis of a chromosomal gene in mouse cells.

Authors: A F Faruqi; M Egholm; P M Glazer
Journal: Proc Natl Acad Sci U S A Date: 1998-02-17 Impact factor: 11.205

Review 4. Flow cytometry applications in pharmacodynamics and drug delivery.

Authors: M Ramanathan
Journal: Pharm Res Date: 1997-09 Impact factor: 4.200

5. Oligonucleotides tethered to a short polyguanylic acid stretch are targeted to macrophages: enhanced antiviral activity of a vesicular stomatitis virus-specific antisense oligonucleotide.

Authors: V Prasad; S Hashim; A Mukhopadhyay; S K Basu; R P Roy
Journal: Antimicrob Agents Chemother Date: 1999-11 Impact factor: 5.191

10. A small inhibitor of the interaction between Bax and Bcl-X(L) can synergize with methylprednisolone to induce apoptosis in Bcl-X(L)-overexpressing breast-cancer cells.

Authors: Yee-Joo Tan; Eileen Teng; Anthony E Ting
Journal: J Cancer Res Clin Oncol Date: 2003-07-16 Impact factor: 4.553

Facilitating oligonucleotide delivery: helping antisense deliver on its promise.